問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Infectious Disease

Division of General Internal Medicine

China Medical University Hospital (在職)

Division of Infectious Disease

更新時間:2023-09-19

曾鈺婷
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

44Cases

2025-01-01 - 2031-01-26

Phase III

Active
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
  • Condition/Disease

    Virologically suppressed individuals with HIV-1 infection receiving standard therapy.

  • Test Drug

    Islatravir/Lenacapavir

Participate Sites
5Sites

Recruiting5Sites

2020-01-01 - 2026-06-30

Phase II/III

Active
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance
  • Condition/Disease

    Heavily Treatment Experienced People Living with HIV-1 Infection

  • Test Drug

    Lenacapavir (LEN: previously referred to as GS-6207)

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2024-11-15 - 2033-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2016-08-01 - 2018-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-12-01 - 2025-11-30

Phase III

Completed
A Phase 3, Randomized, Observer‑blind, Active‑control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA‑1083 (SARS‑CoV‑2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age
  • Condition/Disease

    SARS‑CoV‑2 and Influenza

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2022-11-21 - 2023-12-20

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-11-15 - 2012-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2012-07-01 - 2014-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4 5